COEPTIS, Inc.
Category: AI in Marketing
Develops innovative cell therapy platforms while expanding into AI, robotics, and automation through its COEP Venture Group. COEPTIS, Inc. was founded in 2018. The company is led by Dave Mehalick. Based in Wexford, PA. Team size: 11-50. Total funding raised: $10M. Latest round: Series A Preferred Stock. Key investors include Not publicly disclosed.
- Founded
- 2018
- Headquarters
- Wexford, PA
- Team size
- 11-50
- Total funding
- $10M
Value proposition
Provides capital, strategic mentorship, and state-of-the-art AI and RPA tools to optimize marketing and operational efficiency in highly regulated sectors.
Products and solutions
Cell therapy platforms for cancer, autoimmune, and infectious diseases, AI-powered marketing software, Robotic process automation (RPA) tools
Unique value
Integrates deep biotechnology expertise with cutting-edge AI and automation solutions, creating a hybrid innovation model.
Target customer
Biotech companies, tech startups, and industries facing challenging regulatory landscapes requiring AI-powered marketing and automation solutions.
Industries served
Biopharmaceutical, Technology, Healthcare, Finance (potential)
Technology advantage
Acquisition and integration of NexGenAI Solutions Group’s platform that delivers advanced AI-driven marketing and RPA capabilities; strategic establishment of a Technology Division.
How they differentiate
Combines pioneering biotech platform development with advanced AI and automation investments, addressing regulatory challenges with technology-driven solutions.
Main competitors
Sequoia Capital, Andreessen Horowitz, Khosla Ventures
Key partnerships
Deverra Therapeutics, VyGen-Bio, Karolinska Institute, Arketyp Valu
Notable customers
Secured five new clients for its NexGenAI Affiliates Network platform
Major milestones
Launch of COEP Venture Group Acquisition of the NexGenAI Affiliates Network platform Establishment of a Technology Division Rebranding from Coeptis Therapeutics Holdings, Inc. to COEPTIS
Growth metrics
Stock surged over 200% in six months; secured a convertible note and raised funds via Series A Preferred Stock issuance; multiple managed services agreements contributing to recurring revenue.
Market positioning
A hybrid technology-biotech investment vehicle with a unique value proposition in regulated industries.
Geographic focus
Primarily focused on the U.S., with headquarters in Wexford, PA.
Patents and IP
None
About Dave Mehalick
Dave Mehalick has served as the President, Chief Executive Officer, and Chairman of Coeptis Therapeutics since its inception in 2017. He has a proven track record in guiding the company through significant milestones, including its business combination with Bull Horn Holdings Corp. and its expansion from a biopharmaceutical company focused on cell therapy platforms into the technology sector with investments in AI and automation. His leadership has been pivotal in securing worldwide rights for innovative technologies like SNAP-CAR and GEAR-CAR, aiming to revolutionize treatments for cancer and autoimmune diseases.
Official website: https://coeptistx.com